Avience Biomedicals IPO Listing: Opens at Rs 395 (+90%), Surges to Rs 415, 385x Subscription Delivers Spectacular NSE SME Debut

The Avience Biomedicals IPO has delivered one of the most spectacular SME listings seen this month. Shares of Avience Biomedicals opened on NSE SME at Rs 395.20 today, a premium of approximately 90% over the IPO price of Rs 208, and have since extended gains to Rs 414.95, representing a listing-day return of approximately 99.5% for allottees. Ankit Jaiswal, Senior Research Analyst at Univest notes that the Avience Biomedicals IPO listing performance is exceptional even by the standards of the currently buoyant SME IPO market , the 385x overall subscription was a clear signal that institutional and retail demand was extremely strong, but the actual listing has blown past even the most optimistic GMP estimates of Rs 266-278 (approximately 28-33% premium) that were circulating during the subscription period.

The Avience Biomedicals IPO was subscribed 385.32 times on the final day of bidding. Breaking this down by investor category: retail individual investors subscribed 401.36 times, Non-Institutional Investors (NII/HNI) subscribed 597.23 times, and Qualified Institutional Buyers subscribed 196.77 times. All three categories showed exceptional demand, with the NII oversubscription of 597x being particularly notable as it reflects serious institutional and HNI conviction in the Avience Biomedicals IPO thesis. The grey market had been pricing a GMP of Rs 58-70 in the week leading up to listing, implying an expected listing price of Rs 266-278 , approximately 28-33% above issue price. The actual opening of Rs 395.20 (+90%) nearly tripled that GMP estimate, demonstrating how even strong GMP signals can underestimate the market’s appetite for high-conviction SME issues.

Click Here – Get Free Investment Predictions

Avience Biomedicals IPO Listing: Key Data

Parameter	Detail
Avience Biomedicals IPO Issue Price	Rs 208 per share
Listing Open Price	Rs 395.20 (+89.8% vs issue price)
Current LTP (NSE SME: AVIENCE)	Rs 414.95 (+99.5% vs issue price)
Intraday High	Rs 414.95
Intraday Low	Rs 395.20
Overall Subscription	385.32 times
Retail (Individual) Subscription	401.36 times
NII (HNI) Subscription	597.23 times
QIB Subscription	196.77 times
GMP Before Listing	Rs 58-70 → implied Rs 266-278 (+28-33%)
Actual vs GMP	Opened +90% vs GMP estimate of +28-33% , beat by 3x
Issue Size	Rs 30.24 crore (100% fresh issue)
Listing Exchange	NSE SME (Symbol: AVIENCE)
Anchor Investors	Rs 8.52 Cr , Sanshi Fund-I, Meru Investment Fund, Fortune Hands Growth Fund, Shine Star Build Cap

About Avience Biomedicals: The Business Behind the Avience Biomedicals IPO

Track Avience Biomedicals IPO on Univest Screener

Avience Biomedicals Limited is an ISO-certified diagnostics and medical devices company incorporated in recently24, headquartered in Delhi with a manufacturing facility in Noida, Uttar Pradesh. The company’s product portfolio spans the full in-vitro diagnostics (IVD) value chain: rapid test kits for dengue, malaria, syphilis, HIV, and COVID-19 detection; biochemistry analyzers and reagents; hematology analyzers; molecular diagnostics; oxygen concentrators; and viral transport media (VTM). Avience operates exclusively in B2B and B2G markets, serving pathology labs, microbiology labs, hospitals, research centres, and government organisations across India as well as select international markets. The company distributes and trades medical equipment in addition to its in-house manufacturing. As of recently, the company employed 75 permanent and 33 contractual staff members.

The Avience Biomedicals IPO proceeds (Rs 30.24 crore, 100% fresh issue) are being deployed toward: Rs 15.96 crore for setting up a new manufacturing facility at the YEIDA Medical Device Park in Gautam Buddha Nagar, Uttar Pradesh (Industrial Plot No. 70, Sector 28); Rs 8.25 crore for working capital; and the balance for general corporate purposes. The YEIDA Medical Device Park expansion is particularly significant as it represents a fourfold capacity increase plan from the current Noida facility. One key risk the Avience Biomedicals IPO prospectus flagged: approximately 68.44% of revenue in the 10-month period ended recently26 came from trading activities rather than manufacturing, highlighting the company’s dependence on the trading segment despite its manufacturing brand positioning. Another risk is high customer concentration, with the top 10 customers contributing approximately 46.44% of revenue from operations in the same period.

Avience Biomedicals IPO Financials

Period	Revenue (Rs Cr)	PAT (Rs Cr)	EBITDA Margin	PAT Margin
10M FY26 (recently26)	41.94	5.74	24.70%	~13.7%
FY25 (recently25)	45.97	7.23	25.22%	15.86%
FY24 (recently24)	24.37	2.14	16.75%	8.78%

The Avience Biomedicals IPO was issued at a post-IPO P/E of approximately 16.56x at the issue price of Rs 208, based on annualized 10M FY26 earnings and post-issue diluted EPS of Rs 12.56. At the current listing price of Rs 414.95, the implied P/E has expanded to approximately 33x trailing annualized earnings , a significant premium for a company incorporated as recently as recently24. Return on equity stood at 22.38% as of recently26 (50.14% in FY25, reflecting the pre-IPO capital base). The EBITDA margin of approximately 24-25% is healthy for a diagnostics company at this scale, supported by both manufacturing and higher-margin proprietary IVD products. The debt-to-equity ratio of 0.94x reflects meaningful leverage, with total borrowings of Rs 26.73 crore as of recently26, secured against company assets and promoter properties.

Conclusion: Avience Biomedicals IPO Listing Day Analysis

The Avience Biomedicals IPO has delivered an outstanding listing day performance, with allottees sitting on approximately 99.5% gains at the current LTP of Rs 414.95 against the issue price of Rs 208. The 385x subscription, 597x NII demand, and strong anchor investor participation (Sanshi Fund-I, Meru Investment Fund, Fortune Hands Growth Fund) created the demand base for this exceptional listing. For allottees deciding whether to hold or book profits: the Avience Biomedicals IPO is now trading at approximately 33x trailing earnings at a company that is less than 2 years old and still building its manufacturing base. Post-listing SME stocks often see sharp profit-booking after listing day peaks. The YEIDA expansion and the transition from trading-led to manufacturing-led revenues are the medium-term execution milestones to watch. Track the Avience Biomedicals IPO stock live on Univest. Consult a SEBI-registered financial advisor before making any hold or sell decisions.

Download the Univest iOS App or Univest Android App to track the Avience Biomedicals IPO stock and all SME IPO listings on Univest.

Frequently Asked Questions

What is Avience Biomedicals IPO listing price today?

Ans. The Avience Biomedicals IPO listed on NSE SME (symbol: AVIENCE) with an opening price of Rs 395.20, a premium of approximately 90% over the issue price of Rs 208. The stock has since risen to Rs 414.95 as of the latest trade, delivering a listing-day gain of approximately 99.5% for allottees. The intraday range is Rs 395.20 (low) to Rs 414.95 (high).

What was Avience Biomedicals IPO subscription status?

Ans. The Avience Biomedicals IPO was subscribed 385.32 times overall. Retail individual investors subscribed 401.36 times, Non-Institutional Investors (HNI) subscribed 597.23 times, and Qualified Institutional Buyers (QIBs) subscribed 196.77 times. All three categories showed massive demand, with the NII subscription of 597x being particularly exceptional.

What was Avience Biomedicals IPO GMP before listing?

Ans. The Avience Biomedicals IPO GMP (grey market premium) before listing was approximately Rs 58-70, implying an estimated listing price of Rs 266-278 , approximately 28-33% above the issue price of Rs 208. The actual listing at Rs 395.20 (+90%) significantly exceeded all GMP-based predictions, nearly tripling the implied gain from the grey market estimates.

What does Avience Biomedicals do?

Ans. Avience Biomedicals Limited is an ISO-certified diagnostics and medical devices company manufacturing, supplying, and exporting molecular diagnostic solutions. Products include IVD rapid test kits (dengue, malaria, syphilis, HIV, COVID-19), biochemistry analyzers and reagents, hematology analyzers, molecular diagnostics, oxygen concentrators, and viral transport media. The company serves pathology labs, microbiology labs, hospitals, research centres, and government organisations across India and overseas, operating in B2B and B2G markets. Its manufacturing facility is in Noida, Uttar Pradesh.

Should Avience Biomedicals IPO allottees hold or sell on listing?

Ans. Avience Biomedicals IPO allottees are sitting on approximately 99.5% gains at the current LTP of Rs 414.95. For hold vs sell decisions: the stock is now trading at approximately 33x trailing annualized earnings at a company incorporated less than 2 years ago with a high (68%) trading revenue dependence. SME stocks often see sharp profit-booking after listing day peaks due to lower liquidity. The medium-term bull case rests on the YEIDA Medical Device Park expansion and transition to higher manufacturing revenue. Risk-averse investors may choose to book partial profits. Consult a SEBI-registered financial advisor before making any investment decision.

What is Avience Biomedicals IPO issue price and issue size?

Ans. The Avience Biomedicals IPO issue price is Rs 208 per share (upper band of the Rs 196-208 price band). The issue size is Rs 30.24 crore, comprising a 100% fresh issue of 14,53,800 equity shares (excluding 82,200 shares for the market maker). The registrar is Skyline Financial Services Pvt. Ltd. and the lead manager is Fintellectual Corporate Advisors Pvt. Ltd.

What are the risks in Avience Biomedicals IPO post-listing?

Ans. Key risks in the Avience Biomedicals IPO stock post-listing include: (1) high valuation at approximately 33x trailing earnings at current price , expensive for a company less than 2 years old; (2) trading revenue dependence , approximately 68% of revenue from trading rather than manufacturing, which carries lower entry barriers; (3) customer concentration , top 10 customers = 46.44% of revenue; (4) debt-to-equity of 0.94x (Rs 26.73 crore borrowings) secured against promoter assets; (5) SME listing liquidity risk , lower trading volumes post-listing can make exit difficult; and (6) the company’s very short operating history (incorporated recently24).

What is the NSE SME symbol for Avience Biomedicals?

Ans. The NSE SME trading symbol for Avience Biomedicals Limited is AVIENCE. The stock listed on the NSE SME (Emerge) platform today. Track the Avience Biomedicals IPO live price on the Univest Screener or NSE SME platform.